Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
133 results
Heart rhythm, Volume 14, Issue 7, 23 4 2017, Pages 1051-1052 The right timing for the left lead: Now or later? Yilmaz D, van Erven L, Borleffs CJW, Thijssen J
Cited 1 times since 2017 (0.1 per year) source: EuropePMC
JACC. Clinical electrophysiology, Volume 3, Issue 8, 1 1 2017, Pages 887-893 Nationwide Longitudinal Follow-Up of Riata Leads Under Advisory at 3 Annual Screenings: Report From the Netherlands Heart Rhythm Association Device Advisory Committee. Theuns DAMJ, van Erven L, Kimman GP, de Cock CC, Elvan A, Alings MA, van Opstal J, Meine M
Objectives: This study sought to determine prospectively the rate of conductor externalization (CE), and whether this was associated with electrical failure. Background: The Riata family of defibrillator leads was placed under U.S. Food and Drug Administration advisory as of November 28, 2011 because of high rates of CE. Methods: A nationwide cohort established in 2012 of 1,029 patients with recalled Riata leads with 147 CE were followed until death, lead discontinuation, or 3 annual screenings... Abstract
Cited 7 times since 2017 (0.9 per year) source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Volume 19, Issue 1, 1 1 2017, Pages 72-80 Application and comparison of the FADES, MADIT, and SHFM-D risk models for risk stratification of prophylactic implantable cardioverter-defibrillator treatment. van der Heijden AC, van Rees JB, Levy WC, van der Bom JG, Cannegieter SC, de Bie MK, van Erven L, Schalij MJ, Borleffs CJ
Aims: Implantable cardioverter-defibrillator (ICD) treatment is beneficial in selected patients. However, it remains difficult to accurately predict which patients benefit most from ICD implantation. For this purpose, different risk models have been developed. The aim was to validate and compare the FADES, MADIT, and SHFM-D models. Methods and results: All patients receiving a prophylactic ICD at the Leiden University Medical Center were evaluated. Individual model performance was evaluated by C... Abstract
Cited 73 times since 2016 (9.7 per year) source: EuropePMC
Journal of the American College of Cardiology, Volume 68, Issue 19, 1 1 2016, Pages 2047-2055 Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. Brouwer TF, Yilmaz D, Lindeboom R, Buiten MS, Olde Nordkamp LR, Schalij MJ, Wilde AA, van Erven L, Knops RE
Background: Transvenous implantable cardioverter-defibrillators (TV-ICDs) improve survival in patients at risk for sudden cardiac death, but complications remain an important drawback. The subcutaneous ICD (S-ICD) was developed to overcome lead-related complications. Comparison of clinical outcomes of both device types in previous studies was hampered by dissimilar patient characteristics. Objectives: This retrospective study compares long-term clinical outcomes of S-ICD and TV-ICD therapy in a... Abstract
Cited 7 times since 2016 (0.9 per year) source: EuropePMC
The American journal of cardiology, Volume 118, Issue 8, 29 5 2016, Pages 1217-1224 Long-Term Echocardiographic Outcome in Super-Responders to Cardiac Resynchronization Therapy and the Association With Mortality and Defibrillator Therapy. van der Heijden AC, Höke U, Thijssen J, Willem Borleffs CJ, Wolterbeek R, Schalij MJ, van Erven L
Super-response to cardiac resynchronization therapy (CRT) is associated with significant left ventricular (LV) reverse remodeling and improved clinical outcome. The study aimed to: (1) evaluate whether LV reverse remodeling remains sustained during long-term follow-up in super-responders and (2) analyze the association between the course of LV reverse remodeling and ventricular arrhythmias. Of all, primary prevention super-responders to CRT were selected. Super-response was defined as LV end-sys... Abstract
Pacing and clinical electrophysiology : PACE, Volume 39, Issue 6, 29 5 2016, Pages 565-573 Prognostic Impact of Implementation of QRS Characteristics in the Seattle Heart Failure Model in ICD and CRT-D Recipients. VAN DER Heijden AC, Levy WC, VAN Erven L, Schalij MJ, Borleffs CJ
Background: The Seattle Heart Failure Model (SHFM) provides accurate estimates of survival in heart failure (HF) patients. The model is, however, not developed for HF patients with cardiac resynchronization therapy (CRT). The aim of this study was to assess the prognostic value of SHFM combined with QRS morphology and CRT-related change in QRS duration in implantable cardioverter defibrillator (ICD) and CRT defibrillator (CRT-D) recipients. Methods: All patients who underwent prophylactic ICD im... Abstract
Cited 6 times since 2015 (0.7 per year) source: EuropePMC
Heart rhythm, Volume 13, Issue 2, 11 2 2015, Pages 504-510 Troponin levels after ICD implantation with and without defibrillation testing and their predictive value for outcomes: Insights from the SIMPLE trial. Vamos M, Healey JS, Wang J, Duray GZ, Connolly SJ, van Erven L, Vinolas X, Neuzner J, Glikson M, Hohnloser SH
Background: The Shockless IMPLant Evaluation trial randomized 2500 patients receiving a first implantable cardioverter-defibrillator (ICD)/cardiac resynchronization therapy-defibrillator device to have either defibrillation testing (DT) or no DT. It demonstrated that DT did not improve shock efficacy or reduce mortality. Objective: This prospective substudy evaluated the effect of DT on postoperative troponin levels and their predictive value for total and arrhythmic mortality. Methods: Troponin... Abstract
Cited 35 times since 2015 (3.8 per year) source: EuropePMC
Heart rhythm, Volume 12, Issue 6, 4 1 2015, Pages 1169-1176 The clinical course of patients with implantable cardioverter-defibrillators: Extended experience on clinical outcome, device replacements, and device-related complications. van der Heijden AC, Borleffs CJ, Buiten MS, Thijssen J, van Rees JB, Cannegieter SC, Schalij MJ, van Erven L
Background: Large randomized trials demonstrated the beneficial effect of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy-defibrillator (CRT-D) treatments in selected patients. Data on long-term follow-up of patients outside the setting of clinical trials are scarce. Objective: The aim of this study was to evaluate the long-term outcome of ICD and CRT-D recipients. Methods: All patients who underwent ICD (n = 1729 [57%]) or CRT-D (n = 1326 [43%]) implantation a... Abstract
Cited 29 times since 2015 (3.1 per year) source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Volume 17, Issue 5, 16 3 2015, Pages 689-700 How adequate are the current methods of lead extraction? A review of the efficiency and safety of transvenous lead extraction methods. Buiten MS, van der Heijden AC, Schalij MJ, van Erven L
Currently several extraction tools are available in order to allow safe and successful transvenous lead extraction (TLE) of pacemaker and ICD leads; however, no directives exist to guide physicians in their choice of extraction tools and approaches. To aim of the current review is to provide an overview of the success and complication rates of different extraction methods and tools available. A comprehensive search of all published literature was conducted in the databases of PubMed, Embase, Web... Abstract
Cited 12 times since 2014 (1.3 per year) source: EuropePMC
Heart rhythm, Volume 12, Issue 3, 7 1 2014, Pages 533-539 Epicardial leads in adult cardiac resynchronization therapy recipients: a study on lead performance, durability, and safety. Buiten MS, van der Heijden AC, Klautz RJM, Schalij MJ, van Erven L
Background: Transvenous left ventricular (LV) lead placement for cardiac resynchronization therapy-defibrillator (CRT-D) delivery is unsuccessful in 8% to 10% of cases. These patients might benefit from an epicardial lead. However, data on long-term epicardial lead performance are scarce. Furthermore, extracting an epicardial lead requires a rethoracotomy. Objective: The purpose of this study was to determine data on almost a decade of experience with epicardial leads and investigate the safety... Abstract
Cited 60 times since 2014 (6.2 per year) source: EuropePMC
European heart journal, Volume 36, Issue 3, 1 1 2014, Pages 158-169 EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring. Heidbuchel H, Hindricks G, Broadhurst P, Van Erven L, Fernandez-Lozano I, Rivero-Ayerza M, Malinowski K, Marek A, Romero Garrido RF, Löscher S, Beeton I, Garcia E, Cross S, Vijgen J, Koivisto UM, Peinado R, Smala A, Annemans L
Aim: Remote follow-up (FU) of implantable cardiac defibrillators (ICDs) allows for fewer in-office visits in combination with earlier detection of relevant findings. Its implementation requires investment and reorganization of care. Providers (physicians or hospitals) are unsure about the financial impact. The primary end-point of this randomized prospective multicentre health economic trial was the total FU-related cost for providers, comparing Home Monitoring facilitated FU (HM ON) to regular... Abstract
Cited 20 times since 2014 (2 per year) source: EuropePMC
European journal of heart failure, Volume 16, Issue 10, 19 3 2014, Pages 1104-1111 Super-responders to cardiac resynchronization therapy remain at risk for ventricular arrhythmias and benefit from defibrillator treatment. van der Heijden AC, Höke U, Thijssen J, Borleffs CJ, van Rees JB, van der Velde ET, Schalij MJ, van Erven L
Aims: Mortality and ventricular arrhythmias are reduced in patients responding to cardiac resynchronization therapy (CRT). This response is accompanied by improvement in LVEF, and some patients even outgrow original eligibility criteria for implantable cardioverter-defibrillator (ICD) implantation. It is however unclear if these patients still benefit from ICD treatment. The current study aimed to evaluate if the incidence of ICD therapy is related to the extent of CRT response. Methods and resu... Abstract
Cited 14 times since 2014 (1.4 per year) source: EuropePMC
Journal of cardiovascular electrophysiology, Volume 25, Issue 9, 29 5 2014, Pages 998-1004 Chronic kidney disease and implantable cardioverter defibrillator related complications: 16 years of experience. Buiten MS, DE Bie MK, VAN DER Heijden AC, Rotmans JI, Bootsma M, Marc Groeneveld JH, Wolterbeek R, Rabelink TJ, Jukema JW, Schalij MJ, VAN Erven L
Introduction: Implantable cardioverter defibrillator (ICD) implantation has become an accepted therapy for the prevention of sudden cardiac death. However, serious comorbidities such as chronic kidney disease (CKD) are influencing the beneficial effects of ICD therapy. In this study, the association between kidney function and the occurrence of ICD related complications was assessed. Methods: All patients receiving an ICD or cardiac resynchronization therapy-defibrillator between 1996 and 2012 w... Abstract
Expert review of cardiovascular therapy, Volume 12, Issue 7, 16 3 2014, Pages 787-789 Primary prevention implantable cardioverter-defibrillator implantation in elderly patients: is it justified to withhold treatment? van der Heijden AC, van Erven L, Schalij MJ, Borleffs CJ
Implementation of primary prevention implantable cardioverter-defibrillator (ICD) treatment in the current clinical guidelines led to a significant increase in patients that may benefit from implantation of an ICD. Currently non-guideline-guided patient selection takes place by physicians whereby patients at higher age are more frequently excluded for ICD implantation. This editorial focuses on ICD treatment in the elderly and aims to clarify whether it is justified to withhold ICD treatment in... Abstract
Cited 56 times since 2014 (5.5 per year) source: EuropePMC
Heart (British Cardiac Society), Volume 100, Issue 9, 26 4 2014, Pages 685-690 The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Buiten MS, de Bie MK, Rotmans JI, Gabreëls BA, van Dorp W, Wolterbeek R, Trines SA, Schalij MJ, Jukema JW, Rabelink TJ, van Erven L
Aims: Atrial fibrillation (AF) is common in dialysis patients and is associated with increased morbidity and mortality. The pathophysiology may be related to common risk factors for both AF and renal disease or to dialysis-specific factors. The purpose of this study was to determine whether and how AF onset relates to the dialysis procedure itself. Methods: All dialysis patients enrolled in the implantable cardioverter defibrillator-2 (ICD-2) trial until January 2012, who were implanted with an... Abstract
Cited 86 times since 2014 (8.4 per year) source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Volume 16, Issue 5, 4 1 2014, Pages 681-688 Feasibility, safety, and short-term outcome of leadless ultrasound-based endocardial left ventricular resynchronization in heart failure patients: results of the wireless stimulation endocardially for CRT (WiSE-CRT) study. Auricchio A, Delnoy PP, Butter C, Brachmann J, Van Erven L, Spitzer S, Moccetti T, Seifert M, Markou T, Laszo K, Regoli F, Collaborative Study Group
Aims: Left ventricular (LV) endocardial pacing may address the limitations in the selection of an LV pacing site and provide improvements in cardiac resynchronization therapy (CRT) effectiveness. We report on the feasibility, the safety, and the short-term outcome of a leadless ultrasound-based technology for LV endocardial resynchronization in heart failure (HF) patients enroled into the Wireless Stimulation Endocardially for CRT (WiSE-CRT) study. Methods and results: Seventeen HF patients were... Abstract
Cited 7 times since 2013 (0.7 per year) source: EuropePMC
Pacing and clinical electrophysiology : PACE, Volume 37, Issue 1, 2 1 2013, Pages 25-34 Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry. Thijssen J, van den Akker van Marle ME, Borleffs CJ, van Rees JB, de Bie MK, van der Velde ET, van Erven L, Schalij MJ
Background: Although randomized trials have shown the beneficial effect on survival of an implantable cardioverter defibrillator (ICD) as primary prevention therapy in selected patients, data concerning the cost-effectiveness in routine clinical practice remain scarce. Accordingly, the purpose of this study was to assess the cost-effectiveness of primary prevention ICD implantation in the real world. Methods: Patients receiving primary prevention single-chamber or dual-chamber ICD implantation a... Abstract
Cited 5 times since 2013 (0.5 per year) source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Volume 15, Issue 12, 12 2 2013, Pages 1757-1762 Atrial-based pacing has no benefit over ventricular pacing in preventing atrial arrhythmias in adults with congenital heart disease. Opic P, Yap SC, Van Kranenburg M, Van Dijk AP, Budts W, Vliegen HW, Van Erven L, Can A, Sahin G, De Groot NM, Witsenburg M, Roos-Hesselink JW
Aims: To determine whether atrial-based pacing prevents atrial arrhythmias in adults with congenital heart disease (CHD) compared with ventricular pacing. Methods and results: All adult CHD patients from four participating centres with a permanent pacemaker were identified. Patients with permanent atrial arrhythmias at pacemaker implantation and patients who received a pacemaker for treatment of drug-refractory atrial arrhythmias were excluded. The final study population consisted of 211 patient... Abstract
Cited 20 times since 2013 (1.8 per year) source: EuropePMC
Heart (British Cardiac Society), Volume 99, Issue 17, 30 5 2013, Pages 1244-1249 Gender-specific differences in clinical outcome of primary prevention implantable cardioverter defibrillator recipients. van der Heijden AC, Thijssen J, Borleffs CJ, van Rees JB, Höke U, van der Velde ET, van Erven L, Schalij MJ
Objective: To assess differences in clinical outcome of implantable cardioverter-defibrillator (ICD) treatment in men and women. Design: Prospective cohort study. Setting: University Medical Center. Patients: 1946 primary prevention ICD recipients (1528 (79%) men and 418 (21%) women). Patients with congenital heart disease were excluded for this analysis. Main outcome measures: All-cause mortality, ICD therapy (antitachycardia pacing and shock) and ICD shock. Results: During a median follow-up o... Abstract
Cited 26 times since 2013 (2.4 per year) source: EuropePMC
Heart (British Cardiac Society), Volume 99, Issue 14, 23 4 2013, Pages 1018-1023 Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical practice. de Bie MK, Thijssen J, van Rees JB, Putter H, van der Velde ET, Schalij MJ, van Erven L
Objective: To assess the proportion of current implantable cardioverter defibrillator (ICD) recipients who would be suitable for a subcutaneous lead ICD (S-ICD). Design: A retrospective cohort study. Setting: Tertiary care facility in the Netherlands. Patients: All patients who received a single- or dual-chamber ICD in the Leiden University Medical Center between 2002 and 2011. Patients with a pre-existent indication for cardiac pacing were excluded. Main outcome measure: Suitability for an S-IC... Abstract